Immunotherapy
Venom immunotherapy achieves maintenance doses after three up-dosing sessions
A three-session rush venom immunotherapy protocol was safe and effective with nearly all patients achieving maintenance dosing with few systemic reactions, according to a study published in Annals of Allergy, Asthma & Immunology.
Phase 3 colorectal cancer trial misses survival endpoint
A randomized phase 3 trial designed to compare an investigational combination with standard care for certain patients with advanced colorectal cancer failed to meet its primary endpoint of OS.
Gynecologic Cancer Awareness Month: Regimens extend survival; talc linked to ovarian cancer
September is Gynecologic Cancer Awareness Month.
Trial of CAR-T for prostate cancer takes steps toward ‘potentially curative’ therapy
Chimeric antigen receptor T-cell therapy exhibited activity with minimal adverse effects for men with advanced prostate cancer, findings of a first-in-human trial showed.
Study quantifies survival benefit of immunotherapy in metastatic NSCLC
The introduction of immunotherapy to treatment paradigms has improved survival for patients with metastatic non-small cell lung cancer, according to study results.
Head and neck melanoma associated with more adverse prognostic features
Researchers confirmed that head and neck melanomas have distinct biological characteristics that make it more adverse to patients yet more responsive to immunotherapy, according to a study.
Pembrolizumab regimen extends OS in triple-negative breast cancer
Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.
Prostate Cancer updates: Test identifies aggressive disease, diet affects progression risk
National Prostate Cancer Awareness Month is observed every September.
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy
The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.
Keto diet plus experimental drug may shrink pancreatic tumors
The combination of a ketogenic diet and an experimental MNK inhibitor may be able to shrink pancreatic cancer tumors, according to preliminary study findings.